Misplaced Pages

Segesterone acetate/ethinylestradiol

Ethinylestradiol (top) and segesterone acetate (bottom)
Combination of
Segesterone acetate	Progestogen
Ethinylestradiol	Estrogen
Clinical data
Trade names	Annovera
Other names	EE/SGA; EE/SA
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604032
License data	US DailyMed: Segesterone acetate and ethinyl estradiol
Routes of administration	Intravaginal
ATC code	None
Legal status
Legal status	CA: ℞-only US: ℞-only
Identifiers
KEGG	D11654

Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera among others, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin; and ethinylestradiol, an estrogen. It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.

The ring is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use. Unlike NuvaRing, another vaginal ring contraceptive, the combination ring does not need to be refrigerated before being dispensed and can be stored at room temperature up to 30 degrees Celsius.

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018, and in Canada in December 2024.

See also

• Combined injectable birth control § Available forms
• List of combined sex-hormonal preparations

References

1. ^ "Ringza product information". Health Canada. 18 December 2024. Retrieved 26 December 2024.
2. ^ "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
3. "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 8 August 2024. Retrieved 26 December 2024.
4. Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
5. Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
6. ^ "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control" (Press release). TherapeuticsMD. 10 August 2018. Retrieved 10 October 2020 – via Business Wire.
7. "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDA) (Press release). 10 August 2018. Retrieved 10 October 2020.
8. "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.

• Medicine

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Combined hormonal contraceptives
• Genito-urinary system drug stubs